fortissimo study benefits of the treatment of uncontrolled hypertension by perindopril/indapamide...
TRANSCRIPT
FORTISSIMO study
Benefits of the treatment of uncontrolled hypertension by perindopril/indapamide
fixed full-dose combination
1
Karpov YA; FORTISSIMO program. Poster presented at: European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.
Objectives
Evaluate the safety and efficacy of the fixed-dose combination perindopril arginine/indapamide (10/2.5 mg) in reaching the blood pressure target
In patients with uncontrolled hypertension
With previous treatment: fixed or free combination of renin-angiotensin-aldosterone system (RAAS) inhibitors + hydrochlorothiazide (HCTZ)
2
Karpov YA; FORTISSIMO program. Poster presented at: European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.
Design and Methods
Open, prospective, multicenter, observational, noncomparative study
Inclusion criteria: uncontrolled hypertension (160-200 mm Hg)
2120 hypertensive ambulatory patients in 35 regions of Russia
12-week study (5 visits) Switch to drug combination
perindopril/indapamide (10/2.5 mg) Assessment of:
� Office blood pressure dynamics� Blood and urine assays� Quality of life � Treatment compliance
3
Karpov YA; FORTISSIMO program. Poster presented at: European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.
Blood pressure significantly decreased over time After 3 months of treatment, 84% of patients
reached the blood pressure target
4
Karpov YA; FORTISSIMO program. Poster presented at: European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.
Results – Blood pressure
Results - Tolerability
Treatment compliance significantly increased Only 4% of patients had adverse effects Biochemical markers showed no negative changes
5
4.345.35
5.84
3.28
1.36 1.75
4.335.14 5.18
2.82
1.41 1.56
0
1
2
3
4
5
6
7
K+ Glucose Totalcholesterol
Low-densitylipoproteincholesterol
High-densitylipoproteincholesterol
Triglycerides
mm
ol/L
At baseline
After 3 months oftreatment
Karpov YA; FORTISSIMO program. Poster presented at: European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.
Conclusion
Rapid and sustained effect with the drug combination perindopril/indapamide (10/2.5 mg) in patients with uncontrolled hypertension
84% of patients reached the blood pressure target
Treatment: good tolerability
6
Karpov YA; FORTISSIMO program. Poster presented at: European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.